Information regarding the specific price of Velphoro is not publicly available in the provided context. Drug pricing is complex and can vary based on factors such as insurance coverage, pharmacy, location, and dosage.
How is Velphoro typically prescribed?
Velphoro is a chewable tablet used to control serum phosphorus levels in adult patients with chronic kidney disease (CKD) on dialysis. It is taken with meals [1].
What is the active ingredient in Velphoro?
Velphoro's active ingredient is ferric trichloride hexahydrate [1].
When did Velphoro receive FDA approval?
The U.S. Food and Drug Administration (FDA) approved Velphoro in October 2014 [1].
Are there other treatments for high phosphorus in dialysis patients?
Other treatments for hyperphosphatemia in dialysis patients include dietary phosphorus restriction, increased dialysis efficiency, and other phosphate binders. Velphoro's efficacy and safety profile are considered in relation to these alternatives [1].
What is the patent situation for Velphoro?
Drug patent information, including expiry dates and any challenges, is tracked by resources like DrugPatentWatch.com. Specific details about Velphoro's patent status would require consulting such specialized databases [2].